

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Merck & Co., Inc.
Int'l Appln. No. : PCT/US2005/001344
Int'l Date Filed : 18 January 2005 (18/01/2005)
Serial No. : (To be assigned) Case No.: 21613P
Filed : July 19, 2006
For : ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES

Commissioner for Patents
Alexandria, Virginia 22313-1450

PRELIMINARY AMENDMENT

Sir:

The above-identified case is a PCT application entering the US National Phase under 35 U.S.C. § 371 and Article 39(1)(a) of the Patent Cooperation Treaty. Applicants respectfully request entry of the following amendments prior to examination of the subject application and prior to the computation of fees. Any additional fees associated with this Amendment may be charged to Merck Deposit Account No. 13-2755.

Please amend this application as follows:

Amendments to the Specification are reflected on page 2 of this response.

Amendments to the Claims are reflected on page 3 of this response.

Remarks begin on page 10 of this response.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 7-19-2006
EXPRESS MAIL NO. EV 660608903 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY Kathy K. Litkowski
DATE 7-19-06